Similarly, Kono et al. reported a phase I clinical cancer vaccination research in 10 HLA-A*2402 (+) patients with advanced ESCC who had been intractable to standard ESCC therapy, which combines multiple peptides that were derived from TTK, LY6K, and IMP-3. This evidence concerns the gene TTK and cancer.